메뉴 건너뛰기




Volumn 57, Issue 2, 2011, Pages 186-195

Drug-induced changes in risk/biomarkers and their relationship with renal and cardiovascular long-term outcome in patients with diabetes

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; BIOLOGICAL MARKER; CAPTOPRIL; GLICLAZIDE; INDAPAMIDE PLUS PERINDOPRIL; IRBESARTAN; LOSARTAN; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; PLACEBO; ROSUVASTATIN; TRANSFORMING GROWTH FACTOR BETA;

EID: 79551469139     PISSN: 00099147     EISSN: 15308561     Source Type: Journal    
DOI: 10.1373/clinchem.2010.148395     Document Type: Review
Times cited : (3)

References (72)
  • 1
    • 0035100888 scopus 로고    scopus 로고
    • Biomarkers and surrogate endpoints: Preferred definitions and conceptual framework
    • Biomarkers Definitions Working Group
    • Biomarkers Definitions Working Group. Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther 2001;69:89-95.
    • (2001) Clin Pharmacol Ther , vol.69 , pp. 89-95
  • 2
    • 67650082354 scopus 로고    scopus 로고
    • Use of blood pressure lowering drugs in the prevention of cardiovascular disease: Meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
    • Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009;338:b1665.
    • (2009) BMJ , vol.338
    • Law, M.R.1    Morris, J.K.2    Wald, N.J.3
  • 3
    • 0033055724 scopus 로고    scopus 로고
    • Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: The Steno type 2 randomised study
    • Gaede P, Vedel P, Parving HH, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet 1999;353:617-22.
    • (1999) Lancet , vol.353 , pp. 617-622
    • Gaede, P.1    Vedel, P.2    Parving, H.H.3    Pedersen, O.4
  • 4
    • 77957661790 scopus 로고    scopus 로고
    • How to improve renal outcome in diabetes and hypertension: The importance of early screening for and treatment of microalbuminuria
    • de Zeeuw D, Gansevoort RT, Bakker SJ. How to improve renal outcome in diabetes and hypertension: the importance of early screening for and treatment of microalbuminuria. Eur Nephrol 2009;3:13-5.
    • (2009) Eur Nephrol , vol.3 , pp. 13-15
    • De Zeeuw, D.1    Gansevoort, R.T.2    Bakker, S.J.3
  • 6
    • 77958161566 scopus 로고    scopus 로고
    • Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy
    • Lajer M, Jorsal A, Tarnow L, Parving HH, Rossing P. Plasma growth differentiation factor-15 independently predicts all-cause and cardiovascular mortality as well as deterioration of kidney function in type 1 diabetic patients with nephropathy. Diabetes Care 2010;33:1567-72.
    • (2010) Diabetes Care , vol.33 , pp. 1567-1572
    • Lajer, M.1    Jorsal, A.2    Tarnow, L.3    Parving, H.H.4    Rossing, P.5
  • 7
    • 68149170224 scopus 로고    scopus 로고
    • Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes
    • Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol 2009;20:1813-21.
    • (2009) J Am Soc Nephrol , vol.20 , pp. 1813-1821
    • Ninomiya, T.1    Perkovic, V.2    De Galan, B.E.3    Zoungas, S.4    Pillai, A.5    Jardine, M.6
  • 8
    • 0034708947 scopus 로고    scopus 로고
    • The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus
    • Valmadrid CT, Klein R, Moss SE, Klein BE. The risk of cardiovascular disease mortality associated with microalbuminuria and gross proteinuria in persons with older-onset diabetes mellitus. Arch Intern Med 2000;160:1093-100.
    • (2000) Arch Intern Med , vol.160 , pp. 1093-1100
    • Valmadrid, C.T.1    Klein, R.2    Moss, S.E.3    Klein, B.E.4
  • 9
    • 0037378445 scopus 로고    scopus 로고
    • The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study
    • Keane WF, Brenner BM, de Zeeuw D, Grunfeld JP, McGill J, Mitch WE, et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study. Kidney Int 2003;63:1499-507.
    • (2003) Kidney Int , vol.63 , pp. 1499-1507
    • Keane, W.F.1    Brenner, B.M.2    De Zeeuw, D.3    Grunfeld, J.P.4    McGill, J.5    Mitch, W.E.6
  • 13
    • 0030604561 scopus 로고    scopus 로고
    • Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy
    • The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)
    • Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Lancet 1997;349:1857-63.
    • (1997) Lancet , vol.349 , pp. 1857-1863
  • 14
    • 0035922447 scopus 로고    scopus 로고
    • Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes
    • Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851-60.
    • (2001) N Engl J Med , vol.345 , pp. 851-860
    • Lewis, E.J.1    Hunsicker, L.G.2    Clarke, W.R.3    Berl, T.4    Pohl, M.A.5    Lewis, J.B.6
  • 15
    • 0034117953 scopus 로고    scopus 로고
    • The Irbesartan type II diabetic nephropathy trial: Study design and baseline patient characteristics
    • For the Collaborative Study Group
    • Rodby RA, Rohde RD, Clarke WR, Hunsicker LG, Anzalone DA, Atkins RC, et al. The Irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant 2000;15:487-97.
    • (2000) Nephrol Dial Transplant , vol.15 , pp. 487-497
    • Rodby, R.A.1    Rohde, R.D.2    Clarke, W.R.3    Hunsicker, L.G.4    Anzalone, D.A.5    Atkins, R.C.6
  • 17
    • 34248178511 scopus 로고    scopus 로고
    • Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: Post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial
    • Eijkelkamp WB, Zhang Z, Remuzzi G, Parving HH, Cooper ME, Keane WF, et al. Albuminuria is a target for renoprotective therapy independent from blood pressure in patients with type 2 diabetic nephropathy: post hoc analysis from the Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan (RENAAL) trial. J Am Soc Nephrol 2007;18:1540-6.
    • (2007) J Am Soc Nephrol , vol.18 , pp. 1540-1546
    • Eijkelkamp, W.B.1    Zhang, Z.2    Remuzzi, G.3    Parving, H.H.4    Cooper, M.E.5    Keane, W.F.6
  • 19
    • 30944466929 scopus 로고    scopus 로고
    • Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria
    • DOI 10.1111/j.1523-1755.2005.00511.x, PII 4494697
    • Rossing K, Schjoedt KJ, Jensen BR, Boomsma F, Parving HH. Enhanced renoprotective effects of ultrahigh doses of irbesartan in patients with type 2 diabetes and microalbuminuria. Kidney Int 2005;68:1190-8. (Pubitemid 43246436)
    • (2005) Kidney International , vol.68 , Issue.3 , pp. 1190-1198
    • Rossing, K.1    Schjoedt, K.J.2    Jensen, B.R.3    Boomsma, F.4    Parving, H.-H.5
  • 20
    • 34249897487 scopus 로고    scopus 로고
    • Renoprotection of Optimal Antiproteinuric Doses (ROAD) study: A randomized controlled study of benazepril and losartan in chronic renal insufficiency
    • DOI 10.1681/ASN.2006121372
    • Hou FF, Xie D, Zhang X, Chen PY, Zhang WR, Liang M, et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007;18:1889-98. (Pubitemid 46870325)
    • (2007) Journal of the American Society of Nephrology , vol.18 , Issue.6 , pp. 1889-1898
    • Fan, F.H.1    Xie, D.2    Zhang, X.3    Ping, Y.C.4    Wei, R.Z.5    Liang, M.6    Zhi, J.G.7    Jian, P.J.8
  • 21
    • 1042268736 scopus 로고    scopus 로고
    • One-Year Glycemic Control with a Suifonyurea Plus Pioglitazone Versus a Sulfonylurea Plus Metformin in Patients with Type 2 Diabetes
    • DOI 10.2337/diacare.27.1.141
    • Hanefeld M, Brunetti P, Schernthaner GH, Matthews DR, Charbonnel BH. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 2004;27:141-7. (Pubitemid 38196723)
    • (2004) Diabetes Care , vol.27 , Issue.1 , pp. 141-147
    • Hanefeld, M.1    Brunetti, P.2    Schernthaner, G.H.3    Matthews, D.R.4    Charbonnel, B.H.5
  • 23
    • 70349251198 scopus 로고    scopus 로고
    • Oral paricalcitol in the treatment of patients with CKD and proteinuria: A randomized trial
    • Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N. Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009;54:647-52.
    • (2009) Am J Kidney Dis , vol.54 , pp. 647-652
    • Fishbane, S.1    Chittineni, H.2    Packman, M.3    Dutka, P.4    Ali, N.5    Durie, N.6
  • 24
    • 49849104171 scopus 로고    scopus 로고
    • Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: A randomized double-blind pilot trial
    • Alborzi P, Patel NA, Peterson C, Bills JE, Bekele DM, Bunaye Z, et al. Paricalcitol reduces albuminuria and inflammation in chronic kidney disease: a randomized double-blind pilot trial. Hypertension 2008;52:249-55.
    • (2008) Hypertension , vol.52 , pp. 249-255
    • Alborzi, P.1    Patel, N.A.2    Peterson, C.3    Bills, J.E.4    Bekele, D.M.5    Bunaye, Z.6
  • 25
    • 0030827539 scopus 로고    scopus 로고
    • Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment
    • Tonolo G, Ciccarese M, Brizzi P, Puddu L, Secchi G, Calvia P, et al. Reduction of albumin excretion rate in normotensive microalbuminuric type 2 diabetic patients during long-term simvastatin treatment. Diabetes Care 1997;20:1891-5.
    • (1997) Diabetes Care , vol.20 , pp. 1891-1895
    • Tonolo, G.1    Ciccarese, M.2    Brizzi, P.3    Puddu, L.4    Secchi, G.5    Calvia, P.6
  • 26
    • 78049392231 scopus 로고    scopus 로고
    • Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: The ESPLANADE Trial
    • Ruggenenti P, Perna A, Tonelli M, Loriga G, Motterlini N, Rubis N, et al. Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: The ESPLANADE Trial. Clin J Am Soc Nephrol 2010.
    • (2010) Clin J Am Soc Nephrol
    • Ruggenenti, P.1    Perna, A.2    Tonelli, M.3    Loriga, G.4    Motterlini, N.5    Rubis, N.6
  • 31
    • 77951036335 scopus 로고    scopus 로고
    • Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?
    • discussion 468
    • Lambers Heerspink HJ, de Zeeuw D. Debate: PRO position. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol;31:458-61; discussion 468.
    • Am J Nephrol , vol.31 , pp. 458-461
    • Lambers Heerspink, H.J.1    De Zeeuw, D.2
  • 32
    • 49149087718 scopus 로고    scopus 로고
    • Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): A multicentre, randomised, double-blind, controlled trial
    • Mann JF, Schmieder RE, McQueen M, Dyal L, Schumacher H, Pogue J, et al. Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-53.
    • (2008) Lancet , vol.372 , pp. 547-553
    • Mann, J.F.1    Schmieder, R.E.2    McQueen, M.3    Dyal, L.4    Schumacher, H.5    Pogue, J.6
  • 33
    • 42049107348 scopus 로고    scopus 로고
    • Telmisartan, ramipril, or both in patients at high risk for vascular events
    • Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med 2008;358:1547-59.
    • (2008) N Engl J Med , vol.358 , pp. 1547-1559
    • Yusuf, S.1    Teo, K.K.2    Pogue, J.3    Dyal, L.4    Copland, I.5    Schumacher, H.6
  • 35
    • 0032737429 scopus 로고    scopus 로고
    • Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients
    • Sharma K, Eltayeb BO, McGowan TA, Dunn SR, Alzahabi B, Rohde R, et al. Captopril-induced reduction of serum levels of transforming growth factor-beta1 correlates with long-term renoprotection in insulin-dependent diabetic patients. Am J Kidney Dis 1999;34:818-23.
    • (1999) Am J Kidney Dis , vol.34 , pp. 818-823
    • Sharma, K.1    Eltayeb, B.O.2    McGowan, T.A.3    Dunn, S.R.4    Alzahabi, B.5    Rohde, R.6
  • 36
    • 0036191924 scopus 로고    scopus 로고
    • Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels
    • Agarwal R, Siva S, Dunn SR, Sharma K. Add-on angiotensin II receptor blockade lowers urinary transforming growth factor-beta levels. Am J Kidney Dis 2002;39:486-92.
    • (2002) Am J Kidney Dis , vol.39 , pp. 486-492
    • Agarwal, R.1    Siva, S.2    Dunn, S.R.3    Sharma, K.4
  • 38
    • 0037024202 scopus 로고    scopus 로고
    • Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure
    • Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Borenstein J. Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure. J Am Coll Cardiol 2002;39:1780-6.
    • (2002) J Am Coll Cardiol , vol.39 , pp. 1780-1786
    • Horwich, T.B.1    Fonarow, G.C.2    Hamilton, M.A.3    MacLellan, W.R.4    Borenstein, J.5
  • 39
    • 0037458095 scopus 로고    scopus 로고
    • Anemia is common in heart failure and is associated with poor outcomes: Insights from a cohort of 12 065 patients with new-onset heart failure
    • Ezekowitz JA, McAlister FA, Armstrong PW. Anemia is common in heart failure and is associated with poor outcomes: insights from a cohort of 12 065 patients with new-onset heart failure. Circulation 2003;107:223-5.
    • (2003) Circulation , vol.107 , pp. 223-225
    • Ezekowitz, J.A.1    McAlister, F.A.2    Armstrong, P.W.3
  • 40
    • 39349106306 scopus 로고    scopus 로고
    • The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes
    • Mohanram A, Zhang Z, Shahinfar S, Lyle PA, Toto RD. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. Kidney Int 2008;73:630-6.
    • (2008) Kidney Int , vol.73 , pp. 630-636
    • Mohanram, A.1    Zhang, Z.2    Shahinfar, S.3    Lyle, P.A.4    Toto, R.D.5
  • 42
    • 77955921322 scopus 로고    scopus 로고
    • What is causing the mortality in treating the anemia of chronic kidney disease: Erythropoietin dose or hemoglobin level?
    • Singh AK. What is causing the mortality in treating the anemia of chronic kidney disease: erythropoietin dose or hemoglobin level? Curr Opin Nephrol Hypertens 2010;19:420-4.
    • (2010) Curr Opin Nephrol Hypertens , vol.19 , pp. 420-424
    • Singh, A.K.1
  • 43
    • 77956704796 scopus 로고    scopus 로고
    • Erythropoietic response and outcomes in kidney disease and type 2 diabetes
    • for the TREAT Investigators
    • Solomon SD, Lewis EF, Eckardt K-U, Lin J, Burdmann EA, de Zeeuw D, et al. for the TREAT Investigators. Erythropoietic response and outcomes in kidney disease and type 2 diabetes. N Engl J Med 2010;363:1146-55.
    • (2010) N Engl J Med , vol.363 , pp. 1146-1155
    • Solomon, S.D.1    Lewis, E.F.2    Eckardt, K.-U.3    Lin, J.4    Burdmann, E.A.5    De Zeeuw, D.6
  • 44
    • 77954594687 scopus 로고    scopus 로고
    • Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: The clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol
    • Strippoli GF. Effects of the dose of erythropoiesis stimulating agents on cardiovascular events, quality of life, and health-related costs in hemodialysis patients: the clinical evaluation of the dose of erythropoietins (C.E. DOSE) trial protocol. Trials 2010;11:70.
    • (2010) Trials , vol.11 , pp. 70
    • Strippoli, G.F.1
  • 46
    • 1642277853 scopus 로고    scopus 로고
    • C-reactive protein modulates risk prediction based on the Framingham Score: Implications for future risk assessment: results from a large cohort study in southern Germany
    • Koenig W, Lowel H, Baumert J, Meisinger C. C-reactive protein modulates risk prediction based on the Framingham Score: implications for future risk assessment: results from a large cohort study in southern Germany. Circulation 2004;109:1349-53.
    • (2004) Circulation , vol.109 , pp. 1349-1353
    • Koenig, W.1    Lowel, H.2    Baumert, J.3    Meisinger, C.4
  • 47
    • 46249124299 scopus 로고    scopus 로고
    • The time for cardiovascular inflammation reduction trials has arrived: How low to go for hsCRP?
    • Ridker PM. The time for cardiovascular inflammation reduction trials has arrived: how low to go for hsCRP? Arterioscler Thromb Vasc Biol 2008;28:1222-4.
    • (2008) Arterioscler Thromb Vasc Biol , vol.28 , pp. 1222-1224
    • Ridker, P.M.1
  • 48
    • 33749434265 scopus 로고    scopus 로고
    • Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes
    • Corrado E, Rizzo M, Muratori I, Coppola G, Novo S. Association of elevated fibrinogen and C-reactive protein levels with carotid lesions in patients with newly diagnosed hypertension or type II diabetes. Arch Med Res 2006;37:1004-9.
    • (2006) Arch Med Res , vol.37 , pp. 1004-1009
    • Corrado, E.1    Rizzo, M.2    Muratori, I.3    Coppola, G.4    Novo, S.5
  • 50
    • 25644432841 scopus 로고    scopus 로고
    • Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes
    • Brantsma AH, Bakker SJ, Hillege HL, de Zeeuw D, de Jong PE, Gansevoort RT. Urinary albumin excretion and its relation with C-reactive protein and the metabolic syndrome in the prediction of type 2 diabetes. Diabetes Care 2005;28:2525-30.
    • (2005) Diabetes Care , vol.28 , pp. 2525-2530
    • Brantsma, A.H.1    Bakker, S.J.2    Hillege, H.L.3    De Zeeuw, D.4    De Jong, P.E.5    Gansevoort, R.T.6
  • 51
    • 0035806626 scopus 로고    scopus 로고
    • Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomized trial and cohort study
    • Albert MA, Danielson E, Rifai N, Ridker PM. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA 2001;286:64-70.
    • (2001) JAMA , vol.286 , pp. 64-70
    • Albert, M.A.1    Danielson, E.2    Rifai, N.3    Ridker, P.M.4
  • 52
    • 0035814945 scopus 로고    scopus 로고
    • Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia
    • Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation 2001;103:1191-3.
    • (2001) Circulation , vol.103 , pp. 1191-1193
    • Ridker, P.M.1    Rifai, N.2    Lowenthal, S.P.3
  • 53
    • 0032169240 scopus 로고    scopus 로고
    • Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
    • Cholesterol and Recurrent Events (CARE) Investigators
    • Ridker PM, Rifai N, Pfeffer MA, Sacks FM, Moye LA, Goldman S, et al. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1998;98:839-44.
    • (1998) Circulation , vol.98 , pp. 839-844
    • Ridker, P.M.1    Rifai, N.2    Pfeffer, M.A.3    Sacks, F.M.4    Moye, L.A.5    Goldman, S.6
  • 56
    • 63649095045 scopus 로고    scopus 로고
    • Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: A prospective study of the JUPITER trial
    • Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, et al. Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet 2009;373:1175-82.
    • (2009) Lancet , vol.373 , pp. 1175-1182
    • Ridker, P.M.1    Danielson, E.2    Fonseca, F.A.3    Genest, J.4    Gotto Jr., A.M.5    Kastelein, J.J.6
  • 57
    • 0037432301 scopus 로고    scopus 로고
    • Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT)
    • Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
    • (2003) Circulation , vol.107 , pp. 1278-1283
    • Anand, I.S.1    Fisher, L.D.2    Chiang, Y.T.3    Latini, R.4    Masson, S.5    Maggioni, A.P.6
  • 58
    • 12944320330 scopus 로고    scopus 로고
    • Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria
    • Gaede P, Hildebrandt P, Hess G, Parving HH, Pedersen O. Plasma N-terminal pro-brain natriuretic peptide as a major risk marker for cardiovascular disease in patients with type 2 diabetes and microalbuminuria. Diabetologia 2005;48:156-63.
    • (2005) Diabetologia , vol.48 , pp. 156-163
    • Gaede, P.1    Hildebrandt, P.2    Hess, G.3    Parving, H.H.4    Pedersen, O.5
  • 59
    • 0034176934 scopus 로고    scopus 로고
    • Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations
    • Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 2000;355:1126-30.
    • (2000) Lancet , vol.355 , pp. 1126-1130
    • Troughton, R.W.1    Frampton, C.M.2    Yandle, T.G.3    Espiner, E.A.4    Nicholls, M.G.5    Richards, A.M.6
  • 60
    • 34247135389 scopus 로고    scopus 로고
    • Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: The STARS-BNP Multicenter Study
    • Jourdain P, Jondeau G, Funck F, Gueffet P, Le Helloco A, Donal E, et al. Plasma brain natriuretic peptide-guided therapy to improve outcome in heart failure: the STARS-BNP Multicenter Study. J Am Coll Cardiol 2007;49:1733-9.
    • (2007) J Am Coll Cardiol , vol.49 , pp. 1733-1739
    • Jourdain, P.1    Jondeau, G.2    Funck, F.3    Gueffet, P.4    Le Helloco, A.5    Donal, E.6
  • 61
    • 59249083643 scopus 로고    scopus 로고
    • BNP-guided vs symptomguided heart failure therapy: The Trial of Intensified vs Standard Medical Therapy in Elderly Patients with Congestive Heart Failure (TIME-CHF) randomized trial
    • Pfisterer M, Buser P, Rickli H, Gutmann M, Erne P, Rickenbacher P, et al. BNP-guided vs symptomguided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial. JAMA 2009;301:383-92.
    • (2009) JAMA , vol.301 , pp. 383-392
    • Pfisterer, M.1    Buser, P.2    Rickli, H.3    Gutmann, M.4    Erne, P.5    Rickenbacher, P.6
  • 62
    • 38949210220 scopus 로고    scopus 로고
    • Effect of a multifactorial intervention on mortality in type 2 diabetes
    • Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008;358:580-91.
    • (2008) N Engl J Med , vol.358 , pp. 580-591
    • Gaede, P.1    Lund-Andersen, H.2    Parving, H.H.3    Pedersen, O.4
  • 63
    • 67349189212 scopus 로고    scopus 로고
    • Renal sodium-glucose transport: Role in diabetes mellitus and potential clinical implications
    • Bakris GL, Fonseca VA, Sharma K, Wright EM. Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications. Kidney Int 2009;75:1272-7.
    • (2009) Kidney Int , vol.75 , pp. 1272-1277
    • Bakris, G.L.1    Fonseca, V.A.2    Sharma, K.3    Wright, E.M.4
  • 64
    • 77953857048 scopus 로고    scopus 로고
    • Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: A randomised, double-blind, placebo-controlled trial
    • Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet 375:2223-33.
    • Lancet , vol.375 , pp. 2223-2233
    • Bailey, C.J.1    Gross, J.L.2    Pieters, A.3    Bastien, A.4    List, J.F.5
  • 65
    • 20044367345 scopus 로고    scopus 로고
    • Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: Effects on albumin excretion, endothelial function and inflammation in a double-blind, randomized clinical trial
    • DOI 10.1038/sj.jhh.1001812
    • Schram MT, van Ittersum FJ, Spoelstra-de Man A, van Dijk RA, Schalkwijk CG, Ijzerman RG, et al. Aggressive antihypertensive therapy based on hydrochlorothiazide, candesartan or lisinopril as initial choice in hypertensive type II diabetic individuals: effects on albumin excretion, endothelial function and inflammation in a doubleblind, randomized clinical trial. J Hum Hypertens 2005;19:429-37. (Pubitemid 40767177)
    • (2005) Journal of Human Hypertension , vol.19 , Issue.6 , pp. 429-437
    • Schram, M.T.1    Van, I.F.J.2    Spoelstra-de, M.A.3    Van, D.R.A.J.M.4    Schalkwijk, C.G.5    Ijzerman, R.G.6    Twisk, J.W.R.7    Stehouwer, C.D.A.8
  • 66
    • 77749283806 scopus 로고    scopus 로고
    • Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy
    • Carlton
    • Eyileten T, Sonmez A, Saglam M, Cakir E, Caglar K, Oguz Y, et al. Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy. Nephrology (Carlton) 2010;15:225-9.
    • (2010) Nephrology , vol.15 , pp. 225-229
    • Eyileten, T.1    Sonmez, A.2    Saglam, M.3    Cakir, E.4    Caglar, K.5    Oguz, Y.6
  • 68
    • 33645550266 scopus 로고    scopus 로고
    • Urinary N-acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination
    • Basturk T, Altuntas Y, Kurklu A, Aydin L, Eren N, Unsal A. Urinary N-acetyl B glucosaminidase as an earlier marker of diabetic nephropathy and influence of low-dose perindopril/indapamide combination. Ren Fail 2006;28:125-8.
    • (2006) Ren Fail , vol.28 , pp. 125-128
    • Basturk, T.1    Altuntas, Y.2    Kurklu, A.3    Aydin, L.4    Eren, N.5    Unsal, A.6
  • 69
    • 48349097293 scopus 로고    scopus 로고
    • Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy
    • Ogawa S, Mori T, Nako K, Ito S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker azelnidipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. Hypertens Res 2008;31:1147-55.
    • (2008) Hypertens Res , vol.31 , pp. 1147-1155
    • Ogawa, S.1    Mori, T.2    Nako, K.3    Ito, S.4
  • 70
    • 67651205786 scopus 로고    scopus 로고
    • Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy
    • Ogawa S, Kobori H, Ohashi N, Urushihara M, Nishiyama A, Mori T, et al. Angiotensin II type 1 receptor blockers reduce urinary angiotensinogen excretion and the levels of urinary markers of oxidative stress and inflammation in patients with type 2 diabetic nephropathy. Biomark Insights 2009;4:97-102.
    • (2009) Biomark Insights , vol.4 , pp. 97-102
    • Ogawa, S.1    Kobori, H.2    Ohashi, N.3    Urushihara, M.4    Nishiyama, A.5    Mori, T.6
  • 71
    • 73249126058 scopus 로고    scopus 로고
    • Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy
    • Sasaki H, Saiki A, Endo K, Ban N, Yamaguchi T, Kawana H, et al. Protective effects of efonidipine, a T- and L-type calcium channel blocker, on renal function and arterial stiffness in type 2 diabetic patients with hypertension and nephropathy. J Atheroscler Thromb 2009;16:568-75.
    • (2009) J Atheroscler Thromb , vol.16 , pp. 568-575
    • Sasaki, H.1    Saiki, A.2    Endo, K.3    Ban, N.4    Yamaguchi, T.5    Kawana, H.6
  • 72
    • 43149110575 scopus 로고    scopus 로고
    • Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes
    • Lund SS, Tarnow L, Stehouwer CD, Schalkwijk CG, Teerlink T, Gram J, et al. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. Eur J Endocrinol 2008;158:631-41.
    • (2008) Eur J Endocrinol , vol.158 , pp. 631-641
    • Lund, S.S.1    Tarnow, L.2    Stehouwer, C.D.3    Schalkwijk, C.G.4    Teerlink, T.5    Gram, J.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.